



## Health and Prosperity through Clinical Trials

### Programme

22<sup>nd</sup> March 2018

| Title   | Presenter   | Role   | Time          | Themes   |
|---|---|--|---------------|--|
| Registration/coffee/introductions                                   |   |  | 9.30 - 9.50   |  |
| Welcome   | Graham Malaghan                                       | NZHR Chair   | 9.50 - 10.00  | Introduce NZHR   |
| Clinical trials yesterday, today and tomorrow                       | Chris Higgins   | NZHR Chief Executive   | 10.00 - 10.30 | <ul style="list-style-type: none"> <li>• Key events and decisions</li> <li>• Trends and projections</li> <li>• Outcomes from NZHR 2017 workshop</li> </ul>               |
| Maximising the benefits of research and clinical trials (session 1) | Michelle Sullivan<br>Julia Mathieson<br>Mike Williams | Director of Clinical Trials, Southern Clinical Trials, Christchurch<br>Lakeland Clinical Trials  | 10.30 - 11.30 | Panel discussion<br><br>The value of commercial trials to New Zealand's economy.<br><br>Opportunities for growing the sector in New Zealand, exploring current barriers. |
| Implementing the health research strategy                           | Lucy Pomeroy<br>Nic Aagaard                           | Senior Research Investment Manager Health Research Council<br>Principal Advisor, Ethics, Quality Assurance and Safety and Health System Improvement and Innovation, Ministry of Health | 11.30 - 12.00 | Cross government collaboration<br><br>Clinical trials workstream   |
| Measuring trends and progress                                       | Lucy Pomeroy<br>Chris Higgins                         |  | 12.00 - 12.30 | ANZCTR database and report<br>HDEC database  |

## Health and Prosperity through Clinical Trials

### Programme

22<sup>nd</sup> March 2018

| Title   | Presenter                              | Role   | Time         | Themes   |
|---|--|--|--------------|--|
| Lunch   |  |  | 12.30 - 1.15 |  |
| Maximising the benefits of research and clinical trials (session 2) | Ed Watson                              | Chief Executive, Middlemore Clinical Trials  | 1.45 - 2.15  | Health service and system benefits<br>Economic benefits<br><br>What publicly funded health providers could keep doing, stop doing and start doing  |
| Therapeutic products regime   | Chris James                            | Group Manager, Medsafe<br>Ministry of Health | 2.15 - 2.45  | <ul style="list-style-type: none"> <li>• Authorising clinical trials products</li> <li>• Regulating medical device and cell and tissue trials</li> <li>• Novel products scrutiny</li> <li>• Publicly accessible comprehensive trials register</li> </ul> |
| Tea/coffee  |  |  | 2.45 - 3.00  |  |
| NEAC review of health research standards                            | Nic Aagaard                            |  | 3.00 - 3.30  |  |
| Summary and priorities for further action                           | Chris Higgins<br><br>Michelle Sullivan |  | 3.30 - 4.00  |  |